Roquefort Therapeutics (LON:ROQ) Trading Down 7.9% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 7.9% on Monday . The company traded as low as GBX 1.21 and last traded at GBX 1.21. Approximately 110,784 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 721,993 shares. The stock had previously closed at GBX 1.31.

Roquefort Therapeutics Stock Performance

The stock has a market cap of £2.03 million, a price-to-earnings ratio of -1.97 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The stock’s 50-day moving average is GBX 1.50 and its 200-day moving average is GBX 1.65.

Insider Activity at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Dr Darrin Disley bought 5,000,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average cost of GBX 170 per share, for a total transaction of £8,500,000. 23.53% of the stock is currently owned by corporate insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.